On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...

Matthew Galea is a features writer for CBR. He spends his day as a high school English teacher, and every other minute watching, thinking and writing about movies and television. From Lon Chaney Jr.'s ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

) has been revised to $5.30 / share. This is a decrease of 10.86% from the prior estimate of $5.95 dated December 18, 2025. The price target is an average of many targets provided by analysts. The ...

Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

HOWL is in the clinic with both WTX-124 and WTX-330 and is set to report initial data from the phase 1 trial of WTX-124 in Q4'23. HOWL's partner JAZZ should file an Investigational New Drug ...